Financial Report: Bristol-Myers Squibb

Bristol-Myers Squibb
 
4Q Revenues: $5.5 billion (+7%)

4Q Earnings: $852 million (+76%)

FY Revenues: $21.2 billion (+9%)

FY Earnings: $3.7 billion (+20%)

Comments: U.S. sales increased 8% to $3.6 billion in the quarter and International sales increased 4% to $1.9 billion. Plavix sales were $ 1.7 billion in the quarter (-3%). Avapro/Avalide sales were down 23% to $195 million. Abilify sales were $737 million (+4%). Reyataz sales were up 11% to $416 million. Sustiva Franchise sales were $412 million (+14%). Baraclude sales were up 20% to $318 million. Sprycel sales were up 34% to $227 million. Onglyza/Kombiglyze sales were $153 million (+112%). R&D expenses remained flat at $1.0 billion in the quarter.